Johnson & Johnson (NYSE: JNJ) reported its second quarter 2025 earnings outcomes in the present day.
Reported gross sales elevated 5.8% year-over-year to $23.7 billion. Operational gross sales development was 4.6%.
Web earnings grew over 18% to $5.5 billion, or $2.29 per share, in comparison with final yr. Adjusted EPS dropped 1.8% to $2.77.
Income and earnings beat expectations.
The corporate noticed gross sales within the US enhance 7.8% to $13.5 billion whereas worldwide gross sales grew 3.2% to $10.2 billion.
Gross sales within the Progressive Drugs phase rose 4.9% to $15.2 billion whereas gross sales within the MedTech phase elevated 7.3% to $8.5 billion.
For full-year 2025, JNJ expects reported gross sales to vary between $93.2-93.6 billion whereas adjusted EPS is anticipated to be $10.80-10.90.
The inventory gained 2% in premarket hours on Wednesday.
